Time to discontinuation of non-vitamin k antagonist oral anticoagulants in patients with non-valvular atrial fibrillation

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Ana Ruigomez

Spanish Research Center Pharmacoepidemologic (CEIFE), Madrid (Spain)

13 More presentations in this session

Presentation thumbnail

Oral anticoagulants and their effect on kidneys function, is warfarin safe?

Associate Professor T. Novikova (Saint Petersburg, RU)

Abstract Slides

Presentation thumbnail

Evaluation of the HAS-BLED, ATRIA and ORBIT bleeding risk scores in newly diagnosed non-valvular atrial fibrillation.

Doctor L. Bergamaschi (Bologna, IT)

Abstract Slides

Presentation thumbnail

Inappropriate dosing of non-vitamin K oral anticoagulants (NOACs) in atrial fibrillation patients in Europe

Ms I. Palau (London, GB)

Presentation thumbnail

Patients with atrial fibrillation exhibit a systemic prothrombotic state attributable to impaired endogenous fibrinolysis

Doctor Y. Gue (Liverpool, GB)

Abstract Slides

Presentation thumbnail

Concomitant oral anticoagulant and antidepressant therapy in patients with atrial fibrillation and risk of stroke and bleeding: a population based cohort study

Professor P. Hjemdahl (Stockholm, SE)

Access the full session

Session thumbnail

Poster Session 5 - Atrial fibrillation and oral anticoagulation 1

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Congress Presentation

State-of-the-art lecture on stroke prevention in atrial fibrillation

Congress Presentation

Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro

Congress Presentation

Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - con

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources